LEIDEN, NETHERLANDS--(Marketwire - June 15, 2012) - Biotech company Pharming Group NV
("Pharming" or "the Company") (NYSE Euronext: PHARM) today provides a
update from its press release dated June 12, 2012.
Study 1310, the Phase III clinical study with RUCONEST® that is
support the submission of a Biologics License Application (BLA) to the US
continues to recruit with additional patients enrolled this week.
of the 75 patients required for the completion of Study 1310 have been
In addition, as announced in Pharming's press release dated December 23,
under the EUR8.4 million private bond, which has now been redeemed in
full, a top-up payment in shares caused by the drop in share price over
last month has become due. Therefore 18,330,106 shares will be issued
bondholders under the terms and conditions of the bond.
As of today, the number of outstanding shares has increased from
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of
medical needs. RUCONEST® is a recombinant human C1 inhibitor approved
treatment of angioedema attacks in patients with HAE in all 27 EU countries
Norway, Iceland and Liechtenstein, and is distributed in the EU by
Orphan Biovitrum (OMX: SOBI). RUCONEST® is partnered with
(NASDAQ: SNTS) in North America where the drug is undergoing Phase III
development. The product is also being evaluated for follow-on
the areas of transplantation and reperfusion injury. The advanced
of the Company include innovative and validated platforms for the
protein therapeutics, technology and processes for the purification
formulation of these products. A feasibility study, using the
transgenic rabbit platform, aimed at the development of recombinant Factor
for the treatment of Haemophilia A is underway with partner, Renova Life,
Additional information is available on the Pharming website,
To download the Pharming Group Investor Relations App, click here.
This press release contains forward looking statements that involve
unknown risks, uncertainties and other factors, which may cause the
results, performance or achievements of the Company to be materially
from the results, performance or achievements expressed or implied by
forward looking statements.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pharming Group N.V. via Thomson Reuters ONE